FRI0485 IN PERIPHERAL PSORIATIC ARTHRITIS DKK-1 AND PTH ARE LOWER THAN IN RHEUMATOID ARTHRITIS AND HEALTHY CONTROLS
A. Fassio, L. Idolazzi, O. Viapiana, C. Benini, E. Vantaggiato, M. Rossini, D. Gatti. Rheumatology, Aoui Verona Reumatologia, Verona, Italy Background: The recent characterization of the canonical WNT pathway in the regulation of bone modeling and remodeling provided important insights for our understanding of the pathophysiology of bone involvement in chronic arthritis [1] . Dkk-1 and sclerostin are the main regulators of WNT/b-catenin signaling, regulating both bone formation and resorption [2] . In a previous our study we showed that in patients with Rheumatoid Arthritis (RA) Dkk-1 is significantly increased and associated with the presence of typical erosions and lower BMD [3] . Objectives: we decided to perform this study in order to compare the serum levels of WNT-pathway regulators alongside bone turnover markers (BTM) and Parathyroid Hormone (PTH) between a group of female patients with PsA and healthy controls (HC) or patients with Rheumatoid Arthritis (RA). Methods: this is a cross-sectional study including 18 patients with PsA classified with the CASPAR criteria, 35 HC, and 28 patients with RA classified with the ACR/EULAR 2010 criteria. Intact N-propeptide of type I collagen (PINP), Cterminal telopeptide of type I collagen (CTX-I), Dickkopf-related-protein 1 (Dkk-1), sclerostin, PTH and 25OH-Vitamin D serum levels were dosed. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
Results: the PsA group showed significantly lower Dkk-1 levels when compared to the HC and RA groups. Dkk-1 in the RA group was also significantly higher than in the HC group. A similar trend was documented also for PTH, however a statistically significant difference was observed only when we comparing the PsA vs RA group (table 1, figure 1). No other statistically significant differences in the other markers were found. Objectives: The GO-VIBRANT study was designed to evaluate the safety and efficacy of intravenous (IV) golimumab (GLM) in adult patients (pts) with active PsA (biologic-naïve). Methods: GO-VIBRANT is a Phase 3, multicenter, randomized, double-blind, placebo (PBO)-controlled trial. Biologic-naïve active PsA pts were randomized (1:1) to IV GLM 2mg/kg at weeks (wk) 0, 4, and every 8 wks thereafter or PBO at wks 0, 4, 12, and 20 with crossover to GLM at wk24. The primary endpoint was ACR20 response at wk14. Multiplicity-controlled endpoints were ACR50, ACR70, PASI 75, change from baseline in HAQ-DI, enthesitis, dactylitis, SF-36 PCS/MCS scores at wk14; and ACR50 and change from baseline in total modified vdH-S (structural damage) score at wk24. Efficacy analyses were based on randomized treatment. Adverse events (AE) through wk24 are reported here. Investigators remain blinded through wk60. Results: 480 pts were randomized (PBO: 239; GLM: 241). The study met its primary and all controlled secondary endpoints. At wk14, significantly greater proportions of GLM pts vs PBO achieved ACR20 (75.1% vs. 21.8%). Also, GLM treatment resulted in significant change from baseline HAQ-DI score (-0.60 vs. -0.12), ACR50 (43.6% vs. 6.3%), PASI 75 (59.2% vs. 13.6%), ACR70 (24.5% vs. 2.1%), change from baseline in enthesitis and dactylitis scores (-1.8 vs. -0.8 and -7.8 vs. -2.8, respectively) , and change from baseline in SF-36 PCS and SF-36 MCS scores (8.65 vs. 2.69 and 5.33 vs. 0.97, respectively) (all p<0.001) at wk14. At wk24, significantly greater proportions of GLM pts vs. PBO pts achieved ACR 50 (53.5% vs. 6.3%, p<0.001). At wk24, there was significantly less progression of structural damage for GLM pts vs PBO as measured by change from baseline in total modified vdH-S score (-0.36 vs. 1.95; p<0.001). ACR20 was significantly higher with GLM than PBO as early as wk2 (45.6% vs. 7.5%; p<0.001). 27.0% of GLM pts (vs. 4.2% PBO) achieved Minimal Disease Activity by wk14. Due to the difference in response rates in GLM vs. PBO treated pts, the number needed to treat for ACR20 at wk14 was 1.9 in a post-hoc analysis (Table) . Through wk24,
